EBS — Emergent BioSolutions Share News
0.000.00%
Last trade - 00:00- $639.03m
- $1.08bn
- $742.90m
US STOCKS ON THE MOVE-CoreWeave, Moderna, Fox Corp
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
Emergent rises on $24 million anthrax vaccine order
U.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
Emergent BioSolutions Inc. reports results for the quarter ended June 30 - Earnings Summary
Emergent BioSolutions swings to Q2 loss on impairment charge; to cut jobs
Brief: Emergent BioSolutions Q2 Revenue USD 234.3 Million
Emergent BioSolutions Inc expected to post earnings of 11 cents a share - Earnings Preview
Brief: Emergent Biosolutions Receives $64.5 Million Contract Modification For Bat® To Support U.S. Biodefense Strategy
Emergent BioSolutions Q1 revenue falls 30%
Brief: Emergent Biosolutions Receives Approval From Singapore Health Sciences Authority
Brief: Emergent Biosolutions And Substipharm Biologics Announce Strategic Manufacturing Partnership To Support Japanese Encephalitis Vaccine In The United States
Brief: Emergent Biosolutions Successfully Refinances Term Loan, Amends Asset-Backed Loan Facility And Increases Financial Flexibility
Brief: Emergent Biosolutions Partners With British Columbia To Supply Narcan® Nasal Spray For The Launch Of The Expanded Bc Take Home Naloxone Program
Brief: Emergent Biosolutions Announces Appointment Of John D. Fowler, Jr. To Board Of Directors
Emergent BioSolutions Q4 revenue falls
Brief: Emergent BioSolutions Q4 Revenue USD 148.7 Million